相关临床试验
0
0 进行中
药物批准
19
批准总数
监管机构
2
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
<p><strong>1. INDICATIONS AND USAGE</strong></p> <p>VERQUVO (vericiguat) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction, who are stabilised after a recent decompensation event requiring IV therapy. Vericiguat is administered in combination with other HF therapies <em>[see 9. CLINICAL STUDIES</em> – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em><em>]</em>.</p>
**4.1 Therapeutic indication(s)** VITRAKVI as monotherapy is indicated for the treatment of adult and pediatric patients with solid tumors - that display a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, - who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and - who have no satisfactory treatment options
**What is Canesten® Plus Antifungal Cream used for?** Canesten® Plus Antifungal Cream is a topical antifungal cream used to treat skin infections with co-existing symptoms of inflammation, e.g. itching, which rapid symptom relief is desired. Canesten® Plus Antifungal Cream is effective against: - Dermatomycoses caused by dermatophytes (e.g. athlete’s foot), yeasts (e.g. candida intertrigo), moulds, and other fungi - Infections of the vaginal areas caused by yeast fungi (candida vulvitis); inflammation of the penis area caused by yeast fungi (candida balanitis) - Skin diseases superinfected with organisms sensitive to clotrimazole If you are not sure whether you should start using Canesten® Plus Antifungal Cream, talk to your doctor or pharmacist.
<p><strong>4.1 Indication(s)</strong></p> <p>Chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4):</p> <p>Adempas is indicated for the treatment of adult patients with WHO functional Class II to III symptoms</p> <ul> <li><p>Inoperable CTEPH,</p></li> <li><p>Persistent or recurrent CTEPH after surgical treatment</p></li> </ul> <p>to improve exercise capacity (see section 5.1.2 – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p> <p>Pulmonary arterial hypertension (PAH, WHO Group 1):</p> <p>Adempas is indicated for the treatment of adult patients with WHO functional class II to III PAH to improve exercise capacity (see section 5.1.2 – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p> <p>Efficacy was shown in patients on riociguat monotherapy or in combination with endothelin receptor antagonists or prostanoids.</p> <p>Studies establishing effectiveness included predominately patients with WHO functional class II-III and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.</p>
<p><strong>4.1 Indication(s)</strong></p> <p>Chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4):</p> <p>Adempas is indicated for the treatment of adult patients with WHO functional Class II to III symptoms</p> <ul> <li><p>Inoperable CTEPH,</p></li> <li><p>Persistent or recurrent CTEPH after surgical treatment</p></li> </ul> <p>to improve exercise capacity (see section 5.1.2 – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p> <p>Pulmonary arterial hypertension (PAH, WHO Group 1):</p> <p>Adempas is indicated for the treatment of adult patients with WHO functional class II to III PAH to improve exercise capacity (see section 5.1.2 – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p> <p>Efficacy was shown in patients on riociguat monotherapy or in combination with endothelin receptor antagonists or prostanoids.</p> <p>Studies establishing effectiveness included predominately patients with WHO functional class II-III and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.</p>
<p><strong>4.1 Indication(s)</strong></p> <p>Chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4):</p> <p>Adempas is indicated for the treatment of adult patients with WHO functional Class II to III symptoms</p> <ul> <li><p>Inoperable CTEPH,</p></li> <li><p>Persistent or recurrent CTEPH after surgical treatment</p></li> </ul> <p>to improve exercise capacity (see section 5.1.2 – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p> <p>Pulmonary arterial hypertension (PAH, WHO Group 1):</p> <p>Adempas is indicated for the treatment of adult patients with WHO functional class II to III PAH to improve exercise capacity (see section 5.1.2 – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p> <p>Efficacy was shown in patients on riociguat monotherapy or in combination with endothelin receptor antagonists or prostanoids.</p> <p>Studies establishing effectiveness included predominately patients with WHO functional class II-III and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.</p>
<p><strong>4.1 Indication(s)</strong></p> <p>EYLEA is indicated for the treatment of</p> <ul> <li>neovascular (wet) age-related macular degeneration (wet AMD) (see section 5.1 “Pharmacodynamic properties” – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</li> <li>macular edema secondary to retinal vein occlusion (branch RVO or central RVO).</li> <li>diabetic macular edema (DME).</li> <li>myopic choroidal neovascularization (myopic CNV).</li> </ul>
暂无资讯文章
